#OncoTwitter
LightNews LightNews
schettinif87.bsky.social
Useful updated treatment algorithms for HR+ #breastcancer from @ilanaschlam.bsky.social

We had them on OncoTwitter, now we have it on #OncSky / #oncosky (still figuring out the best hashtag @erikahamilton9.bsky.social 😁)
November 20, 2024 at 6:48 AM
sasankaatapattu.bsky.social
Remote monitoring + PROs in oncology reduced ED visits & improved symptom management with 80% adherence to weekly/monthly questionnaires. Digital health tools showing real clinical impact. buff.ly/4f6j9us #OncoTwitter #SupportiveCare #DigitalHealth
Digital Health Applications in Oncology: An Opportunity to Seize
Digital health advances have transformed many clinical areas including psychiatric and cardiovascular care. However, digital health innovation is relatively nascent in cancer care, which represents th...
buff.ly
November 19, 2024 at 9:22 PM
katesears.bsky.social
🔬 Conclusion: Perioperative Durvalumab in MIBC = clinically effective + socioeconomically justified

#BladderCancer #GUcancer #OncoTwitter #Immunotherapy #HealthEconomics #Medicalwatch 🚀

www.ejcancer.com/article/S095...
www.ejcancer.com
September 9, 2025 at 4:33 PM
katesears.bsky.social
💡 Clinical Tip: In MBC (esp. HER2+ & TNBC), discuss brain metastasis risk proactively — patient-centered dialogue is key while awaiting trial evidence.
#BreastCancer #BrainMets #MetastaticBC #OncoTwitter #MedicalWatch
August 26, 2025 at 2:44 PM
katesears.bsky.social
✅ Systemic Tx: Peri-op #IO & targeted adjuvant (osimertinib, alectinib) improve DFS/OS
✅ Stage III: CRT ➕ durvalumab (WT) / osimertinib (EGFR+) = new SoC

#GlobalUpdate #MedicalwatchPapers #LungCancer #OncoTwitter #ESMO25
www.annalsofoncology.org/article/S092...
Early and locally advanced non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
Surgical diagnosis should be limited to cases with small high-risk nodules, including those with negative positron emission tomography (PET)–CT findings and/or inability to obtain tissue by less invas...
www.annalsofoncology.org
August 29, 2025 at 2:49 PM
katesears.bsky.social
#GeriOncology #ASCOGuideline #GlobalOnc #CancerCare #OncoTwitter #Medicalwatch
ascopubs.org/doi/pdf/10.1...
Geriatric Assessment: ASCO Global Guideline | JCO Global Oncology
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO G...
ascopubs.org
August 28, 2025 at 2:33 PM
katesears.bsky.social
✅ Highlights the urgent need for equity & global trial harmonization.

❓ Question to think: Should trial standards always reflect the best global care — or adapt to local realities?

#OncoEthics #GlobalOncology #ClinicalTrials #OncoTwitter #Medicalwatch
bmjoncology.bmj.com/content/4/1/...
Inferior control arms in oncology trials in LMICs: contextualised or compromised?
In recent years, cancer drug randomised controlled trials (RCTs) have been criticised for employing a control arm treatment that is inferior or suboptimal to the existing standard of care.1 2 Using an...
bmjoncology.bmj.com
August 27, 2025 at 2:43 PM
katesears.bsky.social
✅ 5-yr survival overall: 98%, but only 36–43% in metastatic stage

#MedicalWatchPapers #OncoTwitter #ProstateCancer #CancerStats

💡 Clinical tip: Early detection + equitable access remain key. Discuss PSA screening with men 55–69y, start earlier for Black men & those with strong family history.
September 2, 2025 at 4:29 PM
openmedicine.bsky.social
#BreastCancer #HER2 #T-DXd #SacituzumabGovitecan #OncoTwitter #MedicalWatch #MBC
academic.oup.com/jnci/advance...
Outcomes of subsequent treatment regimens after trastuzumab deruxtecan in patients with metastatic breast cancer
AbstractBackground. Most patients with metastatic breast cancer (MBC) are eligible for treatment with trastuzumab deruxtecan (T-DXd). No data are available
academic.oup.com
August 15, 2025 at 4:36 PM
ipharmaservices.bsky.social
HUTCHMED’s Orpathys (savolitinib) receives conditional NMPA approval in China for MET-amplified gastric & GEJ adenocarcinoma.
www.ipharmacenter.com/post/orpathy...
#news #media #pharma #pharmaceutical #healthcare #globalhealth #healthforall #OncoTwitter #ASCO26
Orpathys wins conditional NMPA approval for MET‑amplified gastric cancer in China | iPharmaCenter
HUTCHMED has secured conditional approval from China’s National Medical Products Administration for savolitinib, marketed as Orpathys, in a new gastric cancer indication.The decision allows oncologist...
www.ipharmacenter.com
July 8, 2026 at 1:58 PM
katesears.bsky.social
🔮 Future: digital twins, living evidence pipelines & multimodal decision-support at point of care
#AI #Oncology #CancerCare #DigitalHealth #OncoTwitter #MedicalWatch
acsjournals.onlinelibrary.wiley.com/doi/10.1002/...
Artificial intelligence across the cancer care continuum
This review highlights the expanding role of artificial intelligence across the cancer care continuum, from risk prediction to end-of-life care. It emphasizes both the promise of artificial intellige...
acsjournals.onlinelibrary.wiley.com
August 25, 2025 at 2:57 PM
ipharmaservices.bsky.social
#ESMOGI26 - Fanregratinib montre un signal robuste en phase II dans le CCI lié à FGFR2 ipharmacenter.com/post/esmo-ga... #pharma #Oncologie #Oncotwitter #OncoAlert #Cancer #innovation #HUTCHMed #actualités #dernièreminute #news #breakingnews
ESMO Gastrointestinal Cancers Congress 2026 | iPharmaCenter
Fanregratinib Delivers Strong Phase II Signal in FGFR2‑Driven iCCAHUTCHMED tested its FGFR inhibitor fanregratinib (HMPL‑453) in a registration‑oriented Phase II study run at 53 hospitals across China...
ipharmacenter.com
June 29, 2026 at 10:57 AM
ipharmaservices.bsky.social
Enhertu obtient une approbation agnostique des tumeurs dans l'UE pour les tumeurs solides métastatiques HER2-positives www.ipharmacenter.com/post/enhertu...
#actualités #pharma #AutorisationEMA #médias #flashinfo #cancer #oncologie #OncoTwitter #ESMOGI26
Enhertu Gains EU Tumour‑Agnostic Approval For HER2‑Positive Metastatic Solid Tumours | iPharmaCenter
The European Commission (EC) has granted tumor-agnostic approval for Enhertu (trastuzumab deruxtecan) to treat adult patients presenting with unresectable or metastatic HER2-positive solid tumors. Bec...
www.ipharmacenter.com
June 29, 2026 at 5:05 PM
ipharmaservices.bsky.social
#Enhertu Gains EU Tumour‑Agnostic Approval For HER2‑Positive Metastatic Solid Tumours

www.ipharmacenter.com/post/enhertu...

#news #pharma #EMAApproval #media #breaking #cancer #oncology #OncoTwitter #ESMOGI26
Enhertu Gains EU Tumour‑Agnostic Approval For HER2‑Positive Metastatic Solid Tumours | iPharmaCenter
The European Commission (EC) has granted tumor-agnostic approval for Enhertu (trastuzumab deruxtecan) to treat adult patients presenting with unresectable or metastatic HER2-positive solid tumors. Bec...
www.ipharmacenter.com
June 29, 2026 at 5:03 PM
katesears.bsky.social
✅ Barriers: resource gaps, training, access in LMICs

➡️ Clinical practice impact: GA should be mandatory in global oncology to optimize outcomes for older adults.

#GeriatricOncology #ASCO #OncoTwitter #Medicalwatch #CancerCare #GlobalOncology
ascopubs.org/doi/10.1200/...
Geriatric Assessment: ASCO Global Guideline | JCO Global Oncology
ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual, ASCO Guidelines follow ...
ascopubs.org
September 5, 2025 at 8:05 PM
katesears.bsky.social
💡 Clinical Tip: FGFR1 amplification defines a high-risk CRC subset. IRS-based IHC scoring may serve as practical biomarker to identify candidates for novel FGFR1-targeted strategies.

#ColorectalCancer #FGFR1 #Biomarkers #PrecisionOncology #OncoTwitter #Medicalwatch
www.esmoopen.com/article/S205...
FGFR1-amplified colorectal cancer: a distinct prognostic subtype identified through integrated genomic and immunohistochemical profiling
Fibroblast growth factor receptor (FGFR) alterations are established therapeutic targets in cholangiocarcinoma and urothelial carcinoma but remain understudied in colorectal cancer (CRC). This study i...
www.esmoopen.com
September 3, 2025 at 5:47 PM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu melhorou a PFS vs. terapia de 1ª linha no NSCLC não escamoso avançado com mutação HER2. Uma opção direcionada de 1ª linha da AstraZeneca (#$AZN ) & #DaiichiSankyo ipharmacenter.com/post/astraze...
#Cancer #Oncologia #CancerDePulmao #ESMO26 #OncoTwitter #OncoAlert
AstraZeneca–Daiichi Sankyo’s Enhertu Wins DESTINY-Lung04; HUTCHMED’s Tagrisso–Orpathys Pair Wins SAFFRON in MET-Selected EGFR NSCLC
AstraZeneca and Daiichi Sankyo reported that Enhertu (trastuzumab deruxtecan) met its primary endpoint in the DESTINY-Lung04 study, showing a clear and meaningful extension of progression-free surviva...
ipharmacenter.com
August 17, 2026 at 3:00 PM
ipharmaservices.bsky.social
DESTINY-Lung04 : #Enhertu bat chimio+pembro en 1L #CBNPC HER2+
• SSP : 14,3 vs 8,3m
• TRG : 70% vs 44,5%
• SG : 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CancerDuPoumon #HER2
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 2:29 PM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu batte chemio+pembro in 1L #NSCLC HER2+ • PFS: 14,3 vs 8,3m • ORR: 70% vs 44,5% • OS: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notizie #media #TumoreAlPolmone
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 3:44 PM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu supera quimio+pembro em 1L #CPNPC HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #notícias #mídia #CâncerDePulmão
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 3:45 PM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu schlägt Chemo+Pembro in 1L HER2+ #NSCLC
• PFS: 14,3 vs 8,3M
• ORR: 70% vs 44,5%
• OS: 29,3 vs 33,1M

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #Nachrichten #Medien #Lungenkrebs
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 2:29 PM
ipharmaservices.bsky.social
DESTINY-Lung04: #Enhertu supera quimio+pembro en 1L #CPNM HER2+
• SLP: 14,3 vs 8,3m
• TRO: 70% vs 44,5%
• SG: 29,3 vs 33,1m

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #news #media #CáncerDePulmón #HER2
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 2:28 PM
ipharmaservices.bsky.social
DESTINY-Lung04：#Enhertu 在1L HER2突变 #非小细胞肺癌 击败化疗+帕博利珠单抗。
• PFS: 14.3 vs 8.3月
• ORR: 70% vs 44.5%
• OS: 29.3 vs 33.1月

www.ipharmacenter.com/post/iaslc-2...

#WCLC26 #WCLC2026 #OncoAlert #OncoTwitter #新闻 #媒体 #肺癌
IASLC 2026 World Conference on Lung Cancer (#WCLC26) | 2026 | iPharmaCenter
Eight-Year ADAURA Update Shows Osimertinib Continuing to Extend Survival After Surgery in EGFR-Mutated Lung CancerAstraZeneca's osimertinib has maintained a substantial survival advantage nearly a dec...
www.ipharmacenter.com
September 17, 2026 at 3:46 PM
ipharmaservices.bsky.social
DESTINY-Lung04：HER2変異陽性の進行非扁平上皮NSCLCにおいて、#Enhertu が一次治療と比較してPFSを改善。アストラゼネカ (NYSE: #$AZN) と #DaiichiSankyo による標的一次治療の選択肢。https://ipharmacenter.com/post/astrazeneca-daiichi-sankyo-s-enhertu-wins-destiny-lung04-hutchmed-s-tagrisso-orpathys-pair-wins-saf
#がん #腫瘍学 #肺がん #ESMO26 #OncoTwitter #OncoAlert
August 17, 2026 at 3:00 PM
ipharmaservices.bsky.social
DESTINY-Lung04：在 HER2 突变晚期非鳞状 NSCLC 中，与一线疗法相比，#Enhertu 显著改善了 PFS。阿斯利康 (NYSE: #$AZN) 和 #DaiichiSankyo 提供的一线靶向选择。https://ipharmacenter.com/post/astrazeneca-daiichi-sankyo-s-enhertu-wins-destiny-lung04-hutchmed-s-tagrisso-orpathys-pair-wins-saf
#癌症 #肿瘤学 #肺癌 #ESMO26 #OncoTwitter #OncoAlert
August 17, 2026 at 3:01 PM